{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:59:26Z","timestamp":1791932366635,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"35","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014825","name":"Biotechnology Industry Research Assistance Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.vaccine.2022.06.006","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T22:34:18Z","timestamp":1655246058000},"page":"5263-5274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["A Brighton Collaboration standardized template with key considerations for a benefit\/risk assessment for an inactivated viral vaccine against Chikungunya virus"],"prefix":"10.1016","volume":"40","author":[{"given":"Libia Milena","family":"Hernandez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Sumathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushant","family":"Sahastrabuddhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Excler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Kochhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2633-5189","authenticated-orcid":false,"given":"Emily R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Gurwith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3-4","key":"10.1016\/j.vaccine.2022.06.006_b0005","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0264-410X(02)00449-8","article-title":"The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI)","volume":"21","author":"Bonhoeffer","year":"2002","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.006_b0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.vaccine.2014.09.035","article-title":"The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)","volume":"33","author":"Chen","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.06.006_b0015","unstructured":"Chikungunya Transmission. Accessed on 15 Mar, 2022 at https:\/\/www.cdc.gov\/chikungunya\/transmission\/index.html#:~:text=Chikungunya%20virus%20is%20primarily%20transmitted,chikungunya%20virus%20during%20epidemic%20periods."},{"issue":"5","key":"10.1016\/j.vaccine.2022.06.006_b0020","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1473-3099(07)70107-X","article-title":"an epidemic arbovirosis","volume":"7","author":"Pialoux","year":"2007","journal-title":"Lancet Infect Dis"},{"issue":"13","key":"10.1016\/j.vaccine.2022.06.006_b0025","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJMra1406035","article-title":"Chikungunya Virus and the Global Spread of a Mosquito-Borne Disease","volume":"372","author":"Campion","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.06.006_b0030","series-title":"Principle and practice of Clinical Virology","author":"Zuckerman","year":"2005"},{"key":"10.1016\/j.vaccine.2022.06.006_b0035","unstructured":"Chikungunya and dengue, south-west Indian Ocean. 2006. WHO Weekly Epidemiol Rec 2006;81:105\u201316."},{"issue":"8","key":"10.1016\/j.vaccine.2022.06.006_b0040","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1056\/NEJMp078013","article-title":"Chikungunya outbreaks\u2014the globalization of vectorborne diseases","volume":"356","author":"Charrel","year":"2007","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.vaccine.2022.06.006_b0045","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3201\/eid2008.131615","article-title":"Co-circulation of Dengue and Chikungunya Viruses, Al Hudaydah, Yemen, 2012","volume":"20","author":"Rezza","year":"2014","journal-title":"Emerg Infect Dis"},{"issue":"13","key":"10.1016\/j.vaccine.2022.06.006_b0050","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES2014.19.13.20752","article-title":"Emergence of chikungunya fever on the French side of Saint Martin island, October to December 2013","volume":"19","author":"Cassadou","year":"2014","journal-title":"Euro Surveill"},{"issue":"9602","key":"10.1016\/j.vaccine.2022.06.006_b0055","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(07)61779-6","article-title":"Infection with chikungunya virus in Italy: an outbreak in a temperate region","volume":"370","author":"Rezza","year":"2007","journal-title":"Lancet"},{"issue":"39","key":"10.1016\/j.vaccine.2022.06.006_b0060","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2017.22.39.17-00646","article-title":"Detection of a chikungunya outbreak in Central Italy, August to September 2017","volume":"22","author":"Venturi","year":"2017","journal-title":"Euro Surveill."},{"key":"10.1016\/j.vaccine.2022.06.006_b0065","doi-asserted-by":"crossref","unstructured":"Butler D. Health officials push for vaccine against neglected tropical virus; 2018. Available from: http:\/\/www.nature.com\/articles\/d41586-018-01637-7 [cited 2022 Mar 15].","DOI":"10.1038\/d41586-018-01637-7"},{"issue":"suppl 5","key":"10.1016\/j.vaccine.2022.06.006_b0070","doi-asserted-by":"crossref","first-page":"S488","DOI":"10.1093\/infdis\/jiw271","article-title":"Development of Vaccines for Chikungunya Fever","volume":"214","author":"Erasmus","year":"2016","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.006_b0075","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00104-16","article-title":"Vaccine and Therapeutic Options To Control Chikungunya Virus","volume":"31","author":"Powers","year":"2018","journal-title":"Clin Microbiol Rev"},{"issue":"37","key":"10.1016\/j.vaccine.2022.06.006_b0080","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1016\/j.vaccine.2017.07.065","article-title":"Regulatory considerations in development of vaccines to prevent disease caused by Chikungunya virus","volume":"35","author":"Yang","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.06.006_b0085","series-title":"Vaccine Analysis: Strategies, Principles, and Control","first-page":"45","author":"Sanders","year":"2015"},{"issue":"9","key":"10.1016\/j.vaccine.2022.06.006_b0090","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/14760584.2017.1357471","article-title":"Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases","volume":"16","author":"Barrett","year":"2017","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2022.06.006_b0095","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1586\/erv.12.38","article-title":"Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges","volume":"11","author":"Delrue","year":"2012","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2022.06.006_b0100","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41577-020-0334-1","article-title":"Inactivated vaccine for SARS-CoV-2","volume":"20","author":"Risson","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2022.06.006_b0105","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3201\/eid1305.070015","article-title":"Chikungunya virus in US travelers returning from India, 2006","volume":"13","author":"Lanciotti","year":"2007","journal-title":"Emerg Infect Dis"},{"issue":"23","key":"10.1016\/j.vaccine.2022.06.006_b0110","doi-asserted-by":"crossref","first-page":"13005","DOI":"10.1128\/JVI.01780-12","article-title":"Longitudinal Analysis of the Human Antibody Response to Chikungunya Virus Infection: Implications for Serodiagnosis and Vaccine Development","volume":"86","author":"Kam","year":"2012","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2022.06.006_b0115","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/emmm.201200213","article-title":"Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein","volume":"4","author":"Kam","year":"2012","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.vaccine.2022.06.006_b0120","unstructured":"Investigator\u2019s Brochure. Chemical or Approved: Generic name:Purified, Inactivated Chikungunya Virus Vaccine (Adsorbed), BBV87.Effective version and Date: v1.4; 17 November 2020."},{"issue":"3","key":"10.1016\/j.vaccine.2022.06.006_b0125","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/jmv.23187","article-title":"Genetic diversity of Chikungunya virus, India 2006\u20132010: evolutionary dynamics and serotype analyses","volume":"84","author":"Sumathy","year":"2012","journal-title":"J Med Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2022.06.006_b0130","first-page":"1003","article-title":"Chikungunya: epidemiology, pathogenesis, clinical features, management, and prevention","volume":"33","author":"Vairo","year":"2019","journal-title":"Infectious Disease Clinics"},{"key":"10.1016\/j.vaccine.2022.06.006_b0135","unstructured":"Pan American Health Organization Tool for the diagnosis and care of patients with suspected arboviral diseases. Washington, D.C.: PAHO; 2017."},{"issue":"3","key":"10.1016\/j.vaccine.2022.06.006_b0140","first-page":"211","article-title":"Chikungunya virus infection: an overview","volume":"36","author":"Caglioti","year":"2013","journal-title":"New Microbiol"},{"issue":"10","key":"10.1016\/j.vaccine.2022.06.006_b0145","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/infdis\/jiz658","article-title":"Analysis of Humoral Immune Responses in Chikungunya Virus (CHIKV)-Infected Patients and Individuals Vaccinated With a Candidate CHIKV Vaccine","volume":"221","author":"Henss","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.06.006_b0150","unstructured":"US Food and Drug Administration. FDA Briefing Document. Vaccines and Related Biological Products Advisory Committee Meeting. Development of Chikungunya Vaccines: Demonstration of Effectiveness; November 8, 2019. https:\/\/www.fda.gov\/media\/132289\/download."},{"issue":"12","key":"10.1016\/j.vaccine.2022.06.006_b0155","article-title":"Local transmission of chikungunya in Rome and the Lazio region","volume":"13","author":"Vairo","year":"2018","journal-title":"Italy PLoS One"},{"key":"10.1016\/j.vaccine.2022.06.006_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050060","article-title":"Multidisciplinary prospective study of mother-to-child chikungunya virus infections on the island of La R\u00e9union","volume":"5","author":"G\u00e9rardin","year":"2008","journal-title":"PLoS Med"},{"issue":"6","key":"10.1016\/j.vaccine.2022.06.006_b0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006510","article-title":"Mother-to-child transmission of Chikungunya virus: a systematic review and meta-analysis","volume":"12","author":"Contopoulos-Ioannidis","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2022.06.006_b0170","unstructured":"Clinical Study Report. Phase 1 open label clinical trial to evaluate the safety, tolerability and immunogenicity of Chikungunya vaccine in healthy adults of 18 to 50 years Amendment to Protocol No: BBIL\/CHIKV\/I\/2014."},{"key":"10.1016\/j.vaccine.2022.06.006_b0175","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijid.2020.03.073","article-title":"Pre-existing chikungunya virus neutralizing antibodies correlate with risk of symptomatic infection and subclinical seroconversion in a Philippine cohort","volume":"95","author":"Yoon","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2022.06.006_b0180","article-title":"High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines","volume":"9","author":"Yoon","year":"2015","journal-title":"PLoS NeglTrop Dis"},{"key":"10.1016\/j.vaccine.2022.06.006_b0185","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3389\/fimmu.2020.00287","article-title":"Role of T Cells in Chikungunya Virus Infection and Utilizing Their Potential in Anti-Viral Immunity","volume":"11","author":"Poh","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2022.06.006_b0190","unstructured":"World Health Organization. Chikungunya WHO suggested outbreak case definition: Available at: https:\/\/www.who.int\/docs\/default-source\/outbreak-toolkit\/latest-update---11-october\/chik-outbreak-toolbox---25092019.pdf?sfvrsn=209b75c6_2 [accessed in Dec 2020]."},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.006_b0195","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41598-018-20305-4","article-title":"Antibody-mediated enhancement aggravates chikungunya virus infection and disease severity","volume":"8","author":"Lum","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2022.06.006_b0200","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/1743-422X-11-183","article-title":"Long-term persistence of Chikungunya virus neutralizing antibodies in human populations of North Eastern Thailand","volume":"11","author":"Nitatpattana","year":"2014","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2022.06.006_b0205","unstructured":"Development\/Reproductive (pre-, peri-, and post-natal) toxicity study in the New Zealand White Rabbits with Chikungunya Vaccine, BBV87, v1.0; dated 4 February 2022."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22007538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22007538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:17:31Z","timestamp":1759403851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22007538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":41,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0264410X22007538"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.06.006","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Brighton Collaboration standardized template with key considerations for a benefit\/risk assessment for an inactivated viral vaccine against Chikungunya virus","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}